Agrichemicals giant rejected a second takeover offer from US rival Monsanto, which the Swiss-based rival said “continues to gloss over” potential antitrust concerns to a deal.
Monsanto overnight restated a $45 billion, or SFr449 per share, offer for Syngenta but with a $2 billion break fee attached, which would become payable to the Swiss group if the deal were scuppered by antitrust concerns.
“After three meetings over the last month with your antitrust team, we do not believe they have raised any credible theory that could be used to impede our proposed merger on the basis of competition concerns,” Monsanto said in a letter to Syngenta.
“Nevertheless, as a sign of our high degree of confidence in obtaining the necessary regulatory approvals, we are willing to commit to a reverse break-up fee of $2 billion payable if we are unable to consummate the transaction for antitrust reasons within 18 months.”
“Such a fee would be among the highest reverse break-up fees that any company has agreed to.”
Full content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas